Cystadane

Quick links to important sections

Cystadane

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cystadane

Quick Facts

Property Description
Active ingredient Betaine Anhydrous (Trimethylglycine)
Form Oral powder (for solution)
Pharmacological class Metabolic agent, Methyl-group donor
General purpose Supports homocysteine metabolism
Origin Synthetic (Pharmaceutical-grade substance)

Cystadane: Definition and Pharmacological Classification

Cystadane is a prescription medicine and a single active ingredient product (monocomponent) officially classified as a metabolic agent. The drug's active substance is Betaine Anhydrous, which is chemically known as trimethylglycine. As a designated methyl-group donor, it is specifically used for managing certain inherited metabolic conditions. Betaine is categorized primarily for its ability to regulate the concentration of homocysteine within the body. This classification highlights its crucial role in supporting the body’s fundamental biochemical processes.

Composition, Origin, and Pharmaceutical Form

The pharmaceutical preparation consists of synthetically manufactured, pharmaceutical-grade Betaine Anhydrous, delivered as an oral powder or powder for oral solution. This formulation is clinically recognized for its high purity, necessary when treating complex metabolic disorders. Although trimethylglycine is an amino acid derivative that functions as an endogenous substance naturally present in cells, Cystadane ensures a pure and consistent delivery of the compound necessary for therapeutic intervention. Its presentation as a fine oral powder is designed to be easily mixed with liquid for the necessary oral route of administration, facilitating management for both adult and pediatric patients.

General Purpose as a Metabolic Agent

The general purpose of Cystadane is to assist in regulating specific biological processes by chemically facilitating the conversion of one compound into another within the body. It functions as an adjunctive therapy whose core purpose is to provide direct chemical support for the remethylation of homocysteine. The general therapeutic action of this medicine is to promote the conversion of homocysteine into the amino acid methionine, thereby reducing the amount of homocysteine in the bloodstream. This essential metabolic action is intended to help the body manage accumulated homocysteine and contribute to the maintenance of key cellular pathways for patients facing inherited difficulties with homocysteine metabolism.

Regulatory References

  1. EMA EPAR Summary

What side effects are possible with Cystadane?

Possible side effects and safety information

Cystadane (Betaine Anhydrous) has an official safety profile primarily characterized by its impact on plasma metabolite concentrations. The most significant safety concern is the risk of elevated plasma methionine concentrations (Hypermethioninemia), which is classified in some regulatory documents as a Very Common occurrence. Severe Hypermethioninemia has been associated with a serious adverse reaction, cerebral edema (brain swelling), particularly in patients with Cystathionine beta-synthase (CBS) deficiency.


Adverse Reactions by System-Organ Class

Side effects reported in regulatory documents are grouped by the affected body system. Common non-serious effects include reactions in the Gastrointestinal System, such as nausea, diarrhea, and vomiting. Other effects include those related to the Nervous System (e.g., headache) and Psychiatric Disorders (e.g., irritability, depression, sleep disturbance), which are generally classified as Uncommon.

Safety Considerations and Monitoring

The official labeling emphasizes the requirement for mandatory monitoring of plasma methionine concentrations, especially in patients with CBS deficiency. This is necessary to manage the risk of severe Hypermethioninemia and its potential complications. Cases of serious cerebral edema have been reported to occur within two weeks to six months after beginning Betaine Anhydrous therapy in this susceptible patient population. Caution is advised when considering use during pregnancy or breastfeeding due to limited clinical data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Cystadane (Betaine Anhydrous) centers on the risk of metabolic imbalance and subsequent neurological effects.

Element Official Regulatory Statement
Documented Overdose Presentations Elevated plasma methionine concentrations (hypermethioninemia). Clinical manifestations associated with severe outcomes may include morning headaches with vomiting and visual changes.
Physiological Systems Affected Central Nervous System (CNS), particularly manifesting as severe cerebral edema (brain swelling).
Dose-Related or Exposure-Related Factors Overdose risk is officially linked to plasma methionine levels exceeding 1,000 mu mol/L, which requires dose reduction and continuous monitoring.
Population-Specific Overdose Notes The risk of hypermethioninemia and associated complications is a specific concern for patients with Cystathionine Beta-Synthase (CBS) deficiency.

Emergency Action and Monitoring

Element Official Regulatory Statement
Immediate Medical Help Required Seek immediate medical attention for any suspected overdose. Urgent care is required for severe symptoms such as collapse, seizure, or trouble breathing.
Emergency-Response Statements Call a poison control center or emergency room immediately.
Supportive Management Management includes supportive treatment and laboratory monitoring of plasma methionine concentrations. No specific antidote is documented, and some regulatory sources note that no case of overdose has been reported in clinical experience.

Regulatory documents strictly define the overdose risk by the metabolic finding of hypermethioninemia and its potential to cause severe cerebral edema. Due to this potential for a severe outcome, regulators mandate that individuals call a poison control center or emergency room immediately upon suspicion of overdose, and require monitoring of plasma methionine levels to guide subsequent management action.

Therapeutic Uses of Cystadane

What Cystadane Treats: Main Uses and Benefits

Cystadane is a highly specialized medication considered relevant for the management of Homocystinuria in both pediatric and adult patients. This is a rare, severe, inherited disorder characterized by a specific and pathological systemic imbalance where a metabolite, homocysteine, accumulates excessively in the blood. This use represents its primary therapeutic application.

The medication is commonly used to help with the underlying condition that causes symptoms related to systemic imbalance, specifically the high concentrations of homocysteine. This metabolic imbalance is associated with specific inherited enzymatic conditions. Cystadane is applied in addressing this core abnormality, which may be part of symptomatic management alongside a special diet and vitamins.

Cystadane contributes to easing the overall symptom load and supports the patient during difficult episodes. This action may assist with maintaining functional stability and is relevant for easing the long-term risk of severe systemic complications. These symptomatic risks include potential damage to the cardiovascular system (e.g., thromboembolic events), as well as progressive issues affecting the nervous system, eyes, and bones.

“The long-term use of Betaine Anhydrous may contribute to easing the burden associated with hyperhomocysteinemia and supports patients during difficult episodes.”


Quick Fact: Relief for Pathological Biochemical Accumulation

Property Description
Primary Indication Homocystinuria (inherited metabolic disorder)
Symptom Targeted High Homocysteine Blood Concentration (Systemic Imbalance)
Therapeutic Role Adjunctive (part of a management plan with diet/vitamins)
Benefit Focus Reduction of Systemic Risk (Cardiovascular, Ocular, Neurological)

Eligibility and Restrictions for Use

Cystadane (Betaine Anhydrous) is approved for use across a wide range of patients, but official regulatory documents strictly define who is eligible and who is prohibited from using the medicine. The drug is classified as an adjunctive treatment for Homocystinuria (all major types, including CBS, MTHFR, and cbl deficiencies).


Eligibility and Exclusion

Category Official Regulatory Status
Approved Age Groups Adults and Pediatric Patients (use is established, including infants older than 24 days). Geriatric use is acceptable.
Absolute Prohibition Contraindicated in patients with known hypersensitivity to Betaine Anhydrous or any of the formulation's inactive components.
Renal/Hepatic Impairment No dose adjustment or restriction is specified in official labels for patients with renal or hepatic impairment.

Populations with Conditional Use

The medicine is permitted in the following groups, but requires caution or mandated monitoring:

  • Pregnancy: Use is conditional. It should be administered only if the potential benefit justifies the potential risk, as determined by a healthcare provider.
  • Lactation: Conditional use is recommended. Caution must be exercised, as it is unknown whether the active substance is excreted in human milk.
  • CBS Deficiency: Patients with Cystathionine beta-synthase (CBS) deficiency must have their plasma methionine levels closely monitored and kept below 1,000 mu mol/L due to the risk of hypermethioninemia and associated complications like cerebral edema.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cystadane (Betaine Anhydrous) is highly specific, focusing on administrative requirements and the drug's metabolic outcome rather than typical drug-drug interactions.

Interacting Substance Categories Official Constraint or Outcome
Amino acid mixtures, GABA analogues Requires mandated separation of administration timing.
Endogenous Methionine Concentration may increase, especially in a specific patient population.

Timing-Based Separation Rules

Regulatory documents require that the intake of Betaine Anhydrous be separated by at least 30 minutes when co-administered with amino acid mixtures or medicinal products containing Vigabatrin and other GABA analogues. This timing rule is in place to minimize the risk of potential interactions with these substances. The official labeling states that no formal interaction studies have been performed to evaluate the drug's effects on common pharmacokinetic pathways, such as Cytochrome P450 enzymes.

Population-Specific Metabolic Outcome

A critical consideration in the official profile is the risk of elevated plasma methionine concentrations, known as hypermethioninemia. This metabolic outcome is explicitly associated with patients who have Cystathionine beta-synthase (CBS) deficiency. For this population, official restrictions mandate the regular monitoring of plasma methionine levels. This procedural constraint requires dose or dietary modification if methionine levels rise above a specified therapeutic threshold.

Mechanism of Action

Targeted Methyl Group Donation and Enzyme Activation

The mechanism of Betaine Anhydrous begins with its function as a methyl group donor in a highly specific metabolic reaction. Its primary molecular action is to serve as a substrate for the enzyme Betaine-Homocysteine Methyltransferase (BHMT), predominantly found in the liver and kidneys. This interaction initiates an auxiliary pathway for the metabolism of accumulated compounds.


Metabolic Bypass and Homocysteine Conversion

By supplying the necessary methyl group, the drug enables the BHMT enzyme to catalyze the swift remethylation of L-homocysteine into L-methionine. This process results in the sustained conversion of the homocysteine metabolite, supporting its removal from the circulation. This conversion results in a reduction of circulating homocysteine concentration.


Systemic Clearance and Methionine Modulation

The physiological consequence of this sustained conversion is a measurable drop in plasma homocysteine concentration. The mechanism-driven production of methionine can result in excessive methionine accumulation (hypermethioninemia) when downstream methionine metabolism is compromised.

Dosage and Administration Information

The administration of Cystadane (betaine anhydrous) is managed under the direction of a physician experienced in homocystinuria. It is exclusively administered via the oral route as a powder for solution. The medication is typically taken in divided doses, twice daily (BID), to maintain consistent metabolic action.

Dosing Regimens and Titration

The standard starting dosage for adults and pediatric patients 3 years of age and older is 6 grams per day, administered as 3 grams twice daily. For pediatric patients less than 3 years of age, treatment often begins with a weight-based regimen of 100 mg/kg/day, also divided into two daily doses.

The dosage for all patients is individually titrated—gradually increased—based on the patient's response, which is determined by monitoring plasma total homocysteine concentrations. Dosage escalation continues until homocysteine levels are non-detectable or present only in small amounts. While a twice-daily 6 gram dose is standard, daily doses of up to 20 grams have been necessary in some patients to achieve metabolic control.

Preparation and Administration

The prescribed dose of powder must be precisely measured using the scoop provided in the package. The measured amount must be dissolved in 4 to 6 ounces (120 to 180 mL) of water, juice, milk, or infant formula, or alternatively, mixed with food. The resulting mixture must be ingested immediately after it is prepared. If the patient is also taking an amino acid mixture, a 30-minute interval should be allowed between the administration of the two products.

Recent Clinical Evidence

Evidence for Use in Homocystinuria

The core research base examined the agent in the context of Homocystinuria, an inherited metabolic condition associated with high levels of the compound homocysteine in the blood. Given the rarity of the disorder, the evidence base is primarily made up of observational studies, non-interventional multi-centre patient registries, and long-term retrospective analyses. Systematic randomized controlled trials (RCTs), which are standard for common conditions, are not the foundational evidence cited by regulators.

Research examined the agent's effect on plasma total homocysteine concentration, a metabolic marker used in research exploring the condition. Data show patterns related to a reduction in plasma total homocysteine concentrations in the observed populations. Studies also monitored other specific metabolic markers, such as plasma methionine and S-adenosylmethionine (SAM) levels, to characterize the shifts in the body's internal chemistry that were monitored. Furthermore, research explored outcomes related to physiological strain, including the frequency of severe systemic complications.

Research Focused on Specific Deficiency Types

The agent was studied in research populations representing the three main genetic causes of Homocystinuria: Cystathionine beta-synthase (CBS) deficiency, MTHFR deficiency, and Cobalamin cofactor metabolism (cbl) defects. Findings indicate that the pattern of lowered homocysteine levels was observed across all major deficiency types. For patients with CBS deficiency, studies reported how symptoms evolved, specifically describing patterns related to an increase in plasma methionine levels.


Long-Term Studies and Follow-Up Data

A significant portion of the research includes long-term observational periods. Researchers have monitored the agent's use in patient registries over many years—some tracking data for multiple decades. This research provides context but not individual predictions about the long-term course of the condition. While these studies help show what has been observed so far in group patterns, it remains uncertain how the long-term patterns observed relate to specific outcomes, such as neurological or eye-related effects, across all subgroups.


Evidence in Pediatric and Other Study Populations

The agent was evaluated in both pediatric patients, including infants, and adults across the research base. The data show patterns related to the metabolic markers examined in these different age groups. In almost all research scenarios, the agent was studied for use as an adjunctive therapy, meaning it was observed alongside other management strategies, such as diet and vitamin supplementation. Regulatory reviews describe challenges in separating the patterns observed from the effects of these concurrent therapies.


Limitations of the Evidence and Research Gaps

The evidence base for the agent, which was reviewed by regulatory bodies for this rare condition, describes several limitations. The evidence quality varies across studies due to the lack of systematic randomized controlled trials (RCTs), which means that comparative evidence is lacking. Research describes a specific knowledge gap regarding the relationship between the agent's amount in the bloodstream and its influence on homocysteine levels; no correlation has been established between the plasma levels of Betaine Anhydrous and the measured reduction in homocysteine. Furthermore, since the agent is applied in studies examining patient-reported experiences as part of a wider regimen, the long-term effects are not fully established for all clinical outcomes in some subgroups.

Frequently Asked Questions (FAQ)

Common questions about Cystadane (FAQ)

Q: Can Cystadane interact with common vitamins like B6 or B12?

A: Official product information indicates that Cystadane is often used alongside other treatments for homocystinuria, including supplements such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), and folate. Regulatory documents do not list an adverse interaction when Cystadane is used along with these vitamins, which is often the case in treatment.


Q: Why is Cystadane sometimes prescribed along with folic acid?

A: Cystadane is typically prescribed for use along with other therapies. These vitamins, such as folic acid, B6, and B12, are related to the metabolic pathways involved in homocysteine management, and studies of the drug were conducted with patients taking them.


Q: Is it normal to feel a change in appetite when taking Cystadane?

A: The most common non-serious side effects reported in official documents were related to the gastrointestinal system, such as nausea and diarrhea. While changes in appetite are not explicitly listed, the reported common gastrointestinal effects like nausea may indirectly influence appetite.


Q: Does Cystadane interact with common pain relievers like ibuprofen or acetaminophen?

A: Formal drug interaction studies have not been performed with Cystadane. Official labeling requires specific timing rules for co-administration with amino acid mixtures or certain other medications. It is recommended that patients consult their healthcare provider about any concurrent medications.


Q: Can Cystadane be taken on an empty stomach?

A: Official instructions specify that the powder must be dissolved in a liquid (such as water, juice, or milk) or mixed with food before ingestion. The regulatory information does not explicitly prohibit or mandate taking the preparation relative to an empty stomach, only the method of preparation is detailed.


Q: What happens if I miss a dose of Cystadane?

A: Patient information based on regulatory guidance suggests that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose is usually skipped. Patients are advised not to take a double dose to compensate.


Q: What should I do if I experience an unusual reaction after taking Cystadane?

A: If signs of severe side effects, such as a severe headache, vomiting, or changes in vision, are noticed, patients are advised to contact their doctor immediately. For all suspected adverse reactions, reporting to a doctor or regulatory authority is the recommended procedure.


Q: Is the taste of Cystadane powder noticeable, and what can be mixed with it?

A: The powder is required to be dissolved in 4 to 6 ounces of water, juice, milk, or infant formula or mixed with food before it is taken. While one report in a clinical registry noted a 'bad taste' in some instances, the official labeling focuses on acceptable mixing methods.


Q: Is Cystadane considered a cure for homocystinuria or a management treatment?

A: Cystadane is indicated for the treatment of homocystinuria to help reduce elevated homocysteine concentrations. Official information defines it as a methylating agent used as an adjunctive treatment, often alongside dietary restrictions and vitamin supplements.


Q: How does Cystadane differ from betaine supplements sold over the counter?

A: Cystadane is a prescription medicine containing pharmaceutical-grade betaine anhydrous that is approved and regulated specifically for the treatment of homocystinuria. Over-the-counter betaine supplements are classified as dietary aids and are not regulated to the same pharmaceutical standard or formally approved to treat this condition.


Q: What specific type of homocystinuria is Cystadane typically used for?

A: Cystadane is indicated for use in all major inherited causes of homocystinuria. This includes deficiencies in the enzymes Cystathionine beta-synthase (CBS), MTHFR, and various cobalamin cofactor metabolism (cbl) defects.


Q: How quickly should I expect to see an effect after starting Cystadane?

A: Official product information, based on clinical observations, suggests that an initial response in homocysteine plasma concentrations is typically seen within several days to approximately one week after starting therapy.


Q: What is the typical timeframe for Cystadane's full benefits to be seen?

A: The maximum response in terms of homocysteine concentration reduction or reaching a stable level of the drug is generally observed within four to six weeks (approximately one month) of beginning the treatment regimen.


Q: Can Cystadane be taken with a protein-restricted diet?

A: Yes, Cystadane is approved for use as an adjunctive therapy to other treatments. Studies confirming the drug's efficacy were conducted with patients maintaining dietary modifications, which often involves a methionine-restriction diet (a type of protein-restricted diet).


Q: How often are blood tests usually required while taking Cystadane?

A: Plasma homocysteine levels should be checked regularly to monitor the effectiveness of the treatment. For patients with CBS deficiency, plasma methionine concentrations must be closely monitored to manage the risk of complications.


Q: Is Cystadane used for any conditions other than homocystinuria?

A: The official indication approved by the FDA is specifically for the treatment of homocystinuria. While the drug's properties may be relevant to related metabolic disorders, the primary approved use is for this condition.


Q: Can Cystadane impact sleep patterns?

A: Yes, the official safety profile for Cystadane lists sleep disturbance as a possible side effect, though it is categorized as an uncommon occurrence.


Q: Is there a generic version of Cystadane available?

A: The active ingredient, betaine anhydrous, has been sold under both the brand name Cystadane and potentially as a generic prescription equivalent. It is also available over-the-counter as a supplement, but the prescription forms are regulated for homocystinuria.


Q: Do I need a special prescription or form for Cystadane?

A: Cystadane is a prescription medicine used for a rare disease. Because of this, it is often managed as a specialty medication, which may involve specific processes like prior authorization or other documentation required by health plans.


Q: Why is Cystadane considered an 'orphan drug'?

A: Cystadane received its orphan medicine designation because homocystinuria is a rare disease. This designation is given to medicines intended to treat life-threatening or debilitating diseases that affect a very small number of people.


Q: How long has Cystadane been approved for treating homocystinuria?

A: Cystadane received its official orphan medicine designation from European regulatory authorities in July 2001.


Q: Is there a maximum time someone can safely take Cystadane?

A: The treatment is intended for chronic or long-term use to manage homocysteine levels. While some patients have used it for many years, the official safety focus is on continuous monitoring of plasma methionine levels to manage associated risks.


Q: Does Cystadane require a special diet beyond the typical low-methionine diet?

A: For patients with CBS deficiency, dietary modification may be required to keep plasma methionine concentrations below 1,000 mu mol/L. This is a procedural requirement intended to manage the risk of hypermethioninemia.


Q: Is Cystadane available over the counter outside of the US?

A: While the specific product, Cystadane, is a prescription medicine, the active ingredient, betaine anhydrous, is also sold as an over-the-counter dietary supplement in various regions. However, the prescription forms are regulated and specifically approved to treat homocystinuria.

How should Cystadane be stored and disposed of?

Cystadane (betaine anhydrous for oral solution) must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature (15 C to 30 C or 59 F to 86 F); do not store above 25 C and do not freeze.
Protection Keep the bottle tightly closed in its original container to protect the powder from moisture (hygroscopic).
Child Safety Must be kept out of the sight and reach of children; the bottle features a child-resistant cap.

Stability and Disposal

The powder must be used within three months after the initial opening of the bottle. Do not use the product after the printed expiry date. Unused or expired Cystadane must be disposed of in accordance with local requirements. The medicine should not be thrown away via household waste or wastewater; consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cystadane found in:

A-Z Index: